DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Patients with malignant pleural mesothelioma (MPM) that cannot be surgically removed will
receive first-line treatment with standard chemotherapy of cisplatin or carboplatin and
pemetrexed. Two-thirds of the participants in the study will be randomly assigned to also
receive a new treatment called durvalumab.
Durvalumab is an antibody (a type of human protein) that works by blocking a body substance
called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the body's immune system
attack cancer cells. Research has shown that durvalumab can slow tumor growth and shrink
tumors in some people with cancer. Previous studies of combining durvalumab and chemotherapy
showed that this combination is active in advanced mesothelioma.
The purpose of this study is to see whether adding durvalumab to standard chemotherapy will
improve overall survival (OS) in patients with MPM.
Phase:
Phase 3
Details
Lead Sponsor:
PrECOG, LLC.
Collaborators:
AstraZeneca Australasian Lung Cancer Trials Group Thoracic Oncology Group Australasia (TOGA) University of Sydney